Names and pronunciation
(ef′la-peg′ra-stim) Rolvedon
PDF page 1407
Loading InternPractice…
Drug reference
(ef′la-peg′ra-stim) Rolvedon
PDF page 1407
Func. class.: Hemopoietic agent
PDF page 1407
Chem. class.: Granulocyte colony stimulating factor
PDF page 1407
ACTION: Stimulates proliferation and differentiation of neutrophils
PDF page 1407
USES: For chemotherapy-induced neutropenia prophylaxis, to decrease the incidence of febrile neutropenia, in pa- tients with nonmyeloid malignancies re- ceiving myelosuppressive anticancer drugs
PDF page 1407
CONTRAINDICATIONS Hypersensitivity to this product, other granulocyte colony stimulating factors, Eschericha coli proteins Precautions: Pregnancy, breastfeeding, myeloid malignancies, sickle cell disease, leukocytosis, splenic rupture, allergic-type reaction
PDF pages 1407, 1408
SIDE EFFECTS CNS: Fever, fatigue, headache, dizziness, insomnia, peripheral edema GI: Splenic rupture HEMA: Leukocytosis INTEG: Alopecia MISC: Chest pain, hyperuricemia, ana- phylaxis, capillary leak syndrome GU: Glomerulonephritis MS: Skeletal pain RESP: Respiratory distress syndrome
PDF page 1408
INTERACTIONS • Do not use product concomitantly, 2 wk prior to, or 24 hr after administration of cytotoxic chemotherapy • Do not use abemaciclib for ≥48 hr after last dose of this product, if required • Avoid use of eflapegrastim for 21 days after betibeglogene autotemcel infusion NURSING CONSIDERATIONS
PDF page 1408
DOSAGE AND ROUTES Adults: SUBCUT 13.2 mg once per che- motherapy cycle; administer approxi- mately 24 hr after chemotherapy.
PDF page 1408
Available forms: Solution for injection 13.2 mg/0.6 mL
PDF page 1408
Administer: SUBCUT route • Using single-use vials; after dose is withdrawn, do not reenter vial • Inspect solution for discoloration, particulates; if present, do not use • Allow the prefilled syringe to reach room temperature for 30 min prior to use • Give entire contents of prefilled sy- ringe • Do not administer during the period 14 days prior to and 24 hr after cytotoxic chemotherapy • Store in refrigerator; do not freeze; may store at room temperature up to 12 hr; avoid shaking, protect from light
PDF page 1408
Assess: • Allergic reactions, anaphylaxis: rash, urticaria; discontinue product, have emergency equipment nearby • ARDS: dyspnea, fever, tachypnea, occasionally confusion; obtain ABGs, chest x-ray; product may need to be discontinued • Bone pain: give mild analgesics • Blood studies: CBC with differential, platelet count before treatment, 2× weekly; neutrophil counts may be in- creased for 2 days after therapy • B/P, respirations, pulse prior to and during therapy • Pregnancy/breastfeeding: use only if benefits outweigh fetal risk, possible ma- jor birth defects; cautious use in breast- feeding, excretion unknown
PDF page 1408
Evaluate: • Therapeutic response: absence of in- fection
PDF page 1408
Patient and caregiver information: • To notify prescriber immediately of allergic reaction, trouble breathing, ab- dominal pain • To notify provider if dose is missed • To notify provider if pregnancy is planned or suspected or if breastfeeding
PDF page 1408
PHARMACOKINETICS Half-life: 15-80 hr; 20-38 hr (children), Tmax 25 hr
PDF page 1408